Pfizer Q2 FY26: revenue up 9 percent, profit up 19 percent

Exceptional itemResults View source PDF Explain this filing

PFIZER · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.6%Reaction day

₹5021.00

prior close

₹5164.00

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-0.4%+1.0% vs market

Pharmaceuticals peers, median of 157sector-0.1%+0.7% vs sector

On the reaction day the stock moved 1.0 pts more than Nifty Smallcap 250 and 0.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.9

10m

+2.1

15m

+1.5

30m

-1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.6-0.4+1.0-0.1+0.7

Next day

+1.1-0.2+1.3-0.5+1.5

+0.5+0.5+0.1-0.4+0.9

-0.4-0.6+0.2-1.1+0.7

-0.6-1.0+0.3-1.4+0.7

-0.3-1.1+0.8-1.6+1.3

-1.4-2.9+1.5-3.3+1.9

15d

-0.3-3.1+2.8-3.4+3.1

+0.3-3.9+4.2-4.3+4.6

-3.1-5.3+2.3-6.9+3.8

+0.3-6.6+6.9-8.8+9.1

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Pfizer Q2 FY26 revenue from operations grew 9.1 percent YoY to Rs 642.34 crore. Net profit rose 19.4 percent to Rs 189.02 crore versus Rs 158.35 crore last year. Half year revenue was Rs 1,245.39 crore with net profit of Rs 380.77 crore. Statutory auditor BS R and Co LLP issued an unmodified limited review report. Board approved results on November 12, 2025.

Likely market impact

Steady growth in revenue and profits with a clean limited review report. No major red flags from this quarter.